Acquisition by Elms Steve of 8000 shares of Marker Therapeutics at 1.72 subject to Rule 16b-3
| MRKR Stock | USD 1.53 0.02 1.32% |
Slightly above 59% of Marker Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Marker Therapeutics suggests that many traders are alarmed. Marker Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Marker Therapeutics. Many technical investors use Marker Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Marker |
Filed transaction by Marker Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Marker Therapeutics Fundamental Analysis
We analyze Marker Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Marker Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Marker Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Marker Therapeutics stock to make a market-neutral strategy. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics with similar companies.
Peers
Marker Therapeutics Related Equities
| PTIX | Protagenic Therapeutics | 8.33 | ||||
| RNXT | RenovoRx | 4.12 | ||||
| AADI | Aadi Bioscience | 1.93 | ||||
| PMVP | Pmv Pharmaceuticals | 1.42 | ||||
| AGEN | Agenus | 1.29 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| KROS | Keros Therapeutics | 0.27 | ||||
| AVTE | Aerovate Therapeutics | 0.82 | ||||
| BNOX | Bionomics | 1.41 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.60 | ||||
| IKNA | Ikena Oncology | 2.14 | ||||
| ALEC | Alector | 2.82 | ||||
| ACRV | Acrivon Therapeutics, | 3.98 | ||||
| XCUR | Exicure | 6.10 | ||||
| TPST | Tempest Therapeutics | 6.90 |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.